The ROS1 inhibitor entrectinib was developed to properly penetrate the BBB and remain in the central nervous system as a form of prevention and treatment of metastatic tumors in patients with locally advanced or metastatic ROS1-positive NSCLC [42]. The gene discussed is ROS1; the disease is metastatic neoplasm.